Table 5.
miRNA signatures for prognosis and treatment response in TNBC subtype
| miRNA(s) | Patient cohort | Sample | Methodology | Clinical observation(s) | Reference |
|---|---|---|---|---|---|
| miR-10b, miR-21, miR-122a, miR-145, miR-205, miR-210 | 49 TNBC cases | FFPE tissues | SYBR green qRT-PCR (Qiagen NV) | Correlates with shorter disease-free and overall survival. | 164 |
| miR-10b-5p, miR-21-3p, miR-31-5p, miR-125b-5p, miR-130a-3p, miR-155-5p, miR-181a-5p, miR-181b-5p, miR-183-5p, miR-195-5p, miR-451a | 15 TNBC cases | Fresh tissues | SYBR green qRT-PCR (Takara Bio Inc.) | Separates TNBC tissues from normal breast tissue. Signature enriched for miRNAs involved in chemoresistance. | 86 |
| miR-16, miR-125b, miR-155, miR-374a | 173 TNBC cases (LN− [35.8%] vs LN+ [64.2%]) | FFPE tissues | NanoString nCounter | Correlates with shorter overall survival. | 165 |
| miR-21 | 72 TNBC cases (Stage I–II [45.8%] vs Stage III–IV [54.2%]; LN− [51.3%] vs LN+ [48.6%]) | Frozen tissues | SYBR green qRT-PCR (Thermo Fisher Scientific) | Correlates with shorter recurrence-free survival. | 166 |
| 105 early-stage TNBC cases (Stage I [48.5%] vs Stage II [51.5%]; LN− [67.6%] vs LN+ [32.4%]) | FFPE tissue cores | In situ hybridization | High levels in stroma compartment correlate with shorter recurrence-free and breast cancer–specific survival. | 97 | |
| miR-27a, miR-30e, miR-155, miR-493 | 173 TNBC cases (LN− [35.8%] vs LN+ [64.2%]) | FFPE tissues | NanoString nCounter | Divides cases into risk subgroups. | 84 |
| miR-27b, miR-150, miR-342 | 37 TNBC cases | Frozen tissues | Illumina miRNA arrays | Correlates with shorter recurrence-free survival. | 67 |
| miR-190a, miR-200b-3p, miR-512-5p | Eleven TNBC cases (Stage I–II [36.3%] vs Stage III–IV [63.7%]; LN− [27.2%] vs LN+ [72.8%]) treated with different neoadjuvant chemotherapy regimens | Tissue core biopsies | SYBR green qRT-PCR (Exiqon) | Predicts response to treatment. | 85 |
| miR-34b | 39 TNBC cases (Stage I–II [80%] vs Stage III–IV [20%]; LN− [44%] vs LN+ [56%]) | FFPE tissues | TaqMan qRT-PCR (Thermo Fisher Scientific) | Correlates with shorter disease-free and overall survival. | 167 |
| miR-200c, miR-205 | 32 TNBC cases (LN− [50%] vs LN+ [50%]) | FFPE tissues | SYBR green qRT-PCR (Qiagen NV) | Lower levels correlate with LN+ status. | 168 |
| miR-210 | 114 early-stage ER− cases with LN− status | FFPE tissues | TaqMan qRT-PCR (Thermo Fisher Scientific) | Correlates with shorter time to distant metastasis. | 65 |
| 58 TNBC cases (LN− [68.9%] vs LN+ [29.3%]) | Frozen tissues | TaqMan qRT-PCR (Thermo Fisher Scientific) | Correlates with shorter disease- free and overall survival. | 66 | |
| miR-376b, miR-381, miR-409-5p, miR-410, miR-766 | 114 TNBC cases | Frozen tissues | miRNA arrays (Agilent Technologies) | Correlates with shorter distant metastasis-free and breast cancer–specific survival. | 169 |
Note: microRNAs in bold show a recurrent presence in at least three independent studies.
Abbreviations: FFPE, formalin-fixed paraffin-embedded; LN, lymph node status; TNBC, triple-negative breast cancer; miRNA, microRNA; qRT-PCR, quantitative real-time polymerase chain reaction.